Absci Corporation

Absci Corporation entered into an underwriting agreement with Jefferies, J.P. Morgan, TD Securities, and Guggenheim to sell 13,495,277 shares of common stock at $7.41 per share. Net proceeds are estimated at ~$93.5 million after underwriting discounts and offering expenses, with closing expected June 25, 2026. Proceeds will fund advancement of ABS-201, Absci's AI-designed anti-PRLR antibody targeting androgenetic alopecia and endometriosis, plus general working capital. This is a material equity raise that dilutes existing shareholders but provides meaningful clinical-stage runway.

Absci Corporation is offering 13,495,277 shares of common stock at $7.41 per share under its existing shelf registration, raising ~$100 million gross (~$94 million net before expenses). Notably, Eli Lilly and Company is purchasing 5,398,111 shares (~$40 million) of the offering, with underwriters taking the remainder. Shares expected to deliver on or about June 25, 2026. The Lilly participation is strategically significant — a major pharma buyer at $40M validates Absci's AI drug design platform, even as the offering is dilutive to existing holders.

ABSI (ABSI) disclosed the results of its annual meeting of shareholders in an 8-K filing under Item 5.07. Shareholders voted on ratification of the independent auditor. All management-sponsored proposals were approved by majority shareholder vote. Annual meeting results are a routine disclosure that confirms shareholder ratification of the board's composition and compensation practices.

With filed Amendment No. 4 to Schedule 13D disclosing updated beneficial ownership in ABSI (ABSI). The filing covers approximately 7,607,449 shares of ABSI. The position is held for potential M&A activity. Schedule 13D amendments are required when a 5%-or-greater holder's ownership, intent, or plans change materially, providing transparency into concentrated positions that could influence corporate governance or trigger M&A activity.